SpePharm Announces the European Launches of Two New Products: MuGard(R) and Xerotin(R)
Published: Apr 20, 2009
AMSTERDAM--(BUSINESS WIRE)--SpePharm, a pan-European specialty pharmaceutical company dedicated to the provision of high medical value medicines in supportive and critical care, today announced the European introduction of two new products; MuGard® & Xerotin®, aimed at relieving some of the most debilitating side effects experienced by cancer patients. The European roll-out of MuGard® and Xerotin® starting this month with Germany, Italy, UK , Nordic countries and Greece. The rest of Europe will follow over the coming 12 to 18 months.